LOGIN  |  REGISTER
Cue Biopharma
Assertio

DaVita to Participate in the Barclays 2023 Global Healthcare Conference

March 13, 2023 | Last Trade: US$138.48 1.89 -1.35

DENVER, March 13, 2023 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) today announced that its chief financial officer, Joel Ackerman, will participate in a fireside chat with investors at the Barclays 2023 Global Healthcare Conference on Tuesday, March 14, 2023, at 3:05 p.m. EDT.

To view the live webcast, visit the Barclays page here and create a free registration.  

DaVita (NYSE: DVA) is a health care provider focused on transforming care delivery to improve quality of life for patients globally. The company is one of the largest providers of kidney care services in the U.S. and has been a leader in clinical quality and innovation for more than 20 years. DaVita cares for patients at every stage and setting along their kidney health journey—from slowing the progression of kidney disease to helping to support transplantation, from acute hospital care to dialysis at home. As of December 31, 2022, DaVita served 200,000 patients at 2,724 outpatient dialysis centers in the United States. The company also operated 350 outpatient dialysis centers in 11 other countries worldwide. DaVita has reduced hospitalizations, improved mortality, and worked collaboratively to propel the kidney care industry to adopt an equitable and high-quality standard of care for all patients, everywhere. To learn more, visit DaVita.com/About.

Contact Information 
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Last Trade: US$138.48
Daily Change: -1.89 -1.35
Daily Volume: 677,537
Market Cap: US$10.470B

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page